News | April 08, 2025
Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Asahi Kasei Life Science covers a broad range of bioprocess products and services
New research labs and process development services to enable next generation therapeutics
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
Awards highlight Avantor's commitment to the Biopharma industry
Subscribe To Our Newsletter & Stay Updated
